ClinicalTrials.gg
RecruitingNCT07439744Updated Feb 27, 2026

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

An interventional study of Eicosapentaenoic acid (omega-3 fatty acid) and Placebo in Obese Adults and MDD, sponsored by National Science and Technology Council, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2025, registered Feb 2026).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

02

Conditions studied

  • Obese Adults
  • MDD
03

In context

Lead sponsor

National Science and Technology Council, Taiwan is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major depressive disorder.
  • Antidepressant drug-free.

Exclusion criteria

Exclusion Criteria:

  • Schizophrenia
  • Mania
  • Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
  • Obsessive-compulsive disorder
  • Post-traumatic stress disorder
  • Alcohol or drug abuse/dependence (except for nicotine)
  • Active suicidal ideation
  • Serious medical/neurological conditions, especially requiring /non-steroidal anti-inflammatory or therapies or chronic thyroid hormone replacement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Eicosapentaenoic Acid (EPA)

    Sample size (n=25). Four capsules of EPA will be administered at a dosage equal to two grams/day

    Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)

  • Placebo comparator
    Placebo

    Sample size (n=25). Four capsules of Placebo will be administered at a dosage equal to two grams/day

    Dietary Supplement: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Depression Diagnosis

    Patients are diagnosed with depression by utilizing the Mini-International Neuropsychiatric Interview (M.I.N.I.). The screening of emotional disturbances has shown that a total score of 4 or more.

    Time frame: Baseline

  2. Depression Severity

    Depression Severity is assessed by utilizing the 17-item Hamilton Depression Rating Scale (HDRS). A score of ≥ 18 shows a significant level of depression.

    Time frame: Weeks 0, 2, 4, 8, and 12.

  3. Depression Severity

    Depression Severity is assessed by utilizing the Montgomery-Åsberg Depression Rating Scale (MADRS). A score of ≥ 20 shows a significant level of depression.

    Time frame: Weeks 0, 2, 4, 8, and 12.

  4. Concentration of Omega-3 Profile in Blood

    The level of Omega-3 will be assessed by Gas Chromatography based on the retention time.

    Time frame: Baseline and Endpoint

Secondary outcomes

  1. Stress Measurement

    Stress level will be measured by utilizing the Perceived Stress Scale. A score of 26 is considered a reference point for high, potentially clinically significant stress.

    Time frame: Weeks 0, 2, 4, 8, and 12.

  2. Food Frequency Assessment

    Food Frequency Assessment will be measured by using the Food Frequency Questionnaire (FFQ). Statistical thresholds used to identify implausible energy reports, categorize participants by intake levels (e.g., quartiles), or determine high/low risk.

    Time frame: Weeks 0, 2, 4, 8, and 12.

  3. Pleasure Measurement

    Pleasure Measurement will be measured by the Snaith-Hamilton Pleasure Scale (SHPS). Score of 3 or more (with a range of 0-14) to indicate the presence of significant anhedonia

    Time frame: Weeks 0, 2, 4, 8, 12

  4. Fatigue Measurement

    Fatigue will be measured by the Multidimensional Fatigue Inventory (MFI). A total score of 60 or higher is considered indicative of clinically significant fatigue.

    Time frame: Weeks 0, 2, 4, 8, and 12.

07

Study locations

1 of 1 sites recruiting
  • Mind Body Interface Research Center (MBI Lab & Care)
    Taichung, Taichung 404, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 27, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439744
Lead sponsor
National Science and Technology Council, Taiwan
Collaborators
Fondation FondaMental, Fondation pour la Recherche Médicale, Ministry of Science and Technology, Taiwan
Responsible party
Kuan-Pin (Professor, Ministry of Science and Technology, Taiwan) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 1, 2025
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eicosapentaenoic Acid

Start the discussion